Patents
Literature
Patsnap Eureka AI that helps you search prior art, draft patents, and assess FTO risks, powered by patent and scientific literature data.

102 results about "Dextromethorphan" patented technology

This medication is used for temporary relief of coughs without phlegm that are caused by certain infections of the air passages (e.g., sinusitis, common cold). This product should not usually be used for an ongoing cough from smoking or long-term breathing problems (e.g., chronic bronchitis, emphysema) unless directed by your doctor.

Compounds and combinations thereof for treating neurological and psychiatric conditions

Dosage forms, drug delivery systems, and methods related to sustained release of dextromethorphan or improved therapeutic effects are disclosed. Typically, bupropion or a related compound is orally administered to a human being to be treated with, or being treated with, dextromethorphan.
Owner:ANTECIP BIOVENTURES II LLC

Bupropion as a modulator of drug activity

Dosage forms, drug delivery systems, and methods related to immediate or sustained release of dextromethorphan or improved therapeutic effects are disclosed. Typically, bupropion or a related compound is orally administered to a human being to be treated with, or being treated with, dextromethorphan.
Owner:ANTECIP BIOVENTURES II LLC

Bupropion as a modulator of drug activity

Dosage forms, drug delivery systems, and methods related to sustained release of dextromethorphan or improved therapeutic effects are disclosed. Typically, bupropion or a related compound is orally administered to a human being to be treated with, or being treated with, dextromethorphan.
Owner:ANTECIP BIOVENTURES II LLC

Compounds and combinations thereof for treating neurological and psychiatric conditions

Dosage forms, drug delivery systems, and methods related to sustained release of dextromethorphan or improved therapeutic effects are disclosed. Typically, bupropion or a related compound is orally administered to a human being to be treated with, or being treated with, dextromethorphan.
Owner:ANTECIP BIOVENTURES II LLC

Compounds and combinations thereof for treating neurological and psychiatric conditions

Dosage forms, drug delivery systems, and methods related to dextromethorphan or improved therapeutic effects are disclosed. Typically, an antidepressant, such as bupropion or a related compound is orally administered to a human being to be treated with, or being treated with, dextromethorphan.
Owner:ANTECIP BIOVENTURES II LLC

Bupropion as a modulator of drug activity

Dosage forms, drug delivery systems, and methods related to sustained release of dextromethorphan or improved therapeutic effects are disclosed. Typically, bupropion or a related compound is orally administered to a human being to be treated with, or being treated with, dextromethorphan.
Owner:ANTECIP BIOVENTURES II LLC

Treatment of poor metabolizers of dextromethorphan with a combination of bupropion and dextromethorphan

Disclosed herein is a method of safely treating a nervous system condition with a combination of dextromethorphan and bupropion. This method is intended for patients having a neurological condition or a psychiatric condition, such as major depressive disorder, and a CYP2D6 poor metabolizer genotype or a CYP2D6 poor metabolizer phenotype.
Owner:ANTECIP BIOVENTURES II LLC

Compounds and combinations thereof for treating neurological and psychiatric conditions

Dosage forms, drug delivery systems, and methods related to sustained release of dextromethorphan or improved therapeutic effects are disclosed. Typically, bupropion or a related compound is orally administered to a human being to be treated with, or being treated with, dextromethorphan.
Owner:ANTECIP BIOVENTURES II LLC

Compounds and combinations thereof for treating neurological and psychiatric conditions

Dosage forms, drug delivery systems, and methods related to sustained release of dextromethorphan or improved therapeutic effects are disclosed. Typically, bupropion or a related compound is orally administered to a human being to be treated with, or being treated with, dextromethorphan.
Owner:ANTECIP BIOVENTURES II LLC

Compounds and combinations thereof for treating neurological and psychiatric conditions

Dosage forms, drug delivery systems, and methods related to sustained release of dextromethorphan or improved therapeutic effects are disclosed. Typically, an antidepressant, such as bupropion or a related compound is orally administered to a human being to be treated with, or being treated with, dextromethorphan.
Owner:ANTECIP BIOVENTURES II LLC

Compounds and combinations thereof for treating neurological and psychiatric conditions

This disclosure relates to a method of treating a neurological disorder, comprising administering a bupropion, or a combination of a bupropion and a dextromethorphan, to a human being in need thereof, monitoring the human being for Brugada pattern / syndrome, drug reaction with eosinophilia and systemic symptoms, or acute generalized exanthematous pustulosis, and reducing or discontinuing use of the bupropion, or the combination of the bupropion and the dextromethorphan, if the human being develops Brugada pattern / syndrome, subcutaneous tissue disorder, drug reaction with eosinophilia and systemic symptoms (DRESS), or acute generalized exanthematous pustulosis.
Owner:ANTECIP BIOVENTURES II LLC

Compounds and combinations thereof for treating neurological and psychiatric conditions

Dosage forms, drug delivery systems, and methods related to sustained release of dextromethorphan or improved therapeutic effects are disclosed. Typically, bupropion or a related compound is orally administered to a human being to be treated with, or being treated with, dextromethorphan.
Owner:ANTECIP BIOVENTURES II LLC

Compounds and combinations thereof for treating neurological and psychiatric conditions

Dosage forms, drug delivery systems, and methods related to sustained release of dextromethorphan or improved therapeutic effects are disclosed. Typically, an antidepressant, such as bupropion or a related compound is orally administered to a human being to be treated with, or being treated with, dextromethorphan.
Owner:ANTECIP BIOVENTURES II LLC

Treatment of poor metabolizers of dextromethorphan with a combination of bupropion and dextromethorphan

Disclosed herein is a method of safely treating a nervous system condition with a combination of dextromethorphan and bupropion. This method is intended for patients having a neurological condition or a psychiatric condition, such as major depressive disorder, and a CYP2D6 poor metabolizer genotype or a CYP2D6 poor metabolizer phenotype.
Owner:ANTECIP BIOVENTURES II LLC

Bupropion as a modulator of drug activity

Dosage forms, drug delivery systems, and methods related to sustained release of dextromethorphan or improved therapeutic effects are disclosed. Typically, bupropion or a related compound is orally administered to a human being to be treated with, or being treated with, dextromethorphan.
Owner:ANTECIP BIOVENTURES II LLC

Bupropion as a modulator of drug activity

Dosage forms, drug delivery systems, and methods related to sustained release of dextromethorphan or improved therapeutic effects are disclosed. Typically, bupropion or a related compound is orally administered to a human being to be treated with, or being treated with, dextromethorphan.
Owner:ANTECIP BIOVENTURES II LLC

Bupropion as a modulator of drug activity

Dosage forms, drug delivery systems, and methods related to sustained release of dextromethorphan or improved therapeutic effects are disclosed. Typically, bupropion or a related compound is orally administered to a human being to be treated with, or being treated with, dextromethorphan.
Owner:ANTECIP BIOVENTURES II LLC

Bupropion as a modulator of drug activity

Dosage forms, drug delivery systems, and methods related to sustained release of dextromethorphan or improved therapeutic effects are disclosed. Typically, bupropion or a related compound is orally administered to a human being to be treated with, or being treated with, dextromethorphan.
Owner:ANTECIP BIOVENTURES II LLC

Hybridoma cell strain secreting dextromethorphan monoclonal antibody and application thereof

The invention relates to a hybridoma cell strain capable of secreting dextromethorphan monoclonal antibody and application of the hybridoma cell strain, and belongs to the technical field of immunodetection. The monoclonal antibody secreted by the hybridoma cell strain disclosed by the invention has good sensitivity and specificity on dextromethorphan, wherein the IC50 value on the dextromethorphan is 0.162 ng / mL. The monoclonal antibody provided by the invention has no cross reaction on structural analogues of dextromethorphan, such as fentanyl, thilazine, papaverine, morphine and medetomidine, and has good specificity, so that the dextromethorphan with low concentration can be accurately detected.
Owner:JIANGNAN UNIV

Immunochromatography test paper for dextromethorphan hair detection as well as preparation method and application of immunochromatography test paper

The invention relates to immunochromatography test paper for dextromethorphan hair detection as well as a preparation method and application thereof. The immunochromatography test paper comprises a bottom plate, and a sample pad, a gold label pad, a nitrocellulose membrane and a water absorption pad which are sequentially stacked on the bottom plate, the nitrocellulose membrane contains a detection line coated with a dextromethorphan-antigen hemoglobin conjugate and a quality control line coated with goat anti-rabbit IgG (Immunoglobulin G); the content of the dextromethorphan-antigen hemoglobin conjugate in the detection line is 0.0026 to 0.51 [mu] g; the content of goat anti-rabbit IgG (immunoglobulin G) in the quality control line is 0.256 mg to 1.024 mg. According to the detection reagent strip, the detection accuracy can be remarkably improved within the limited range of the content of the dextromethorphan-antigen hemoglobin conjugate on the immunochromatography test paper, and the detection reagent strip is high in sensitivity, good in stability and small in result difference.
Owner:ZHEJIANG ORIENT GENE BIOTECH CO LTD

Dextromethorphan and guaifenesin syrup formulation

A stable pharmaceutical formulation or suspension has a pharmaceutical active agent, agave, and a dilutant. The formulation or suspension has viscosity suitable for drinking.
Owner:GENEXA INC

Compounds and combinations thereof for treating neurological and psychiatric conditions

Dosage forms, drug delivery systems, and methods related to dextromethorphan or improved therapeutic effects are disclosed. Typically, an antidepressant, such as bupropion or a related compound is orally administered to a human being to be treated with, or being treated with, dextromethorphan.
Owner:ANTECIP BIOVENTURES II LLC

Use of dextromethorphan in combination with CYP2D6 and CYP3A4 enzyme inhibitors for the treatment of pain

Methods and compositions for treating pain are provided. Methods for treating pain include administering an effective amount of dextromethorphan or a pharmaceutically acceptable salt thereof in combination with a CYP2D6 enzyme inhibitor and a CYP3A4 enzyme inhibitor to a subject in need thereof. Compositions for treating pain that include dextromethorphan or a pharmaceutically acceptable salt thereof in combination with a CYP2D6 enzyme inhibitor and a CYP3A4 enzyme inhibitor are administered to a subject in need thereof.
Owner:BIOBINA LLC

Dosage forms and methods for enantiomerically enriched or pure bupropion

Described herein are dosage forms of enantiomerically enriched (S)-bupropion or enantiomerically enriched (R)-bupropion. The (S)-bupropion or the (R)-bupropion may be deuterium enriched, or may have natural isotopic abundance. These dosage forms may be administered, either fed or fasted, to treat a condition recited herein, to achieve a certain pharmacokinetic parameter of a bupropion or a metabolite of a bupropion, and / or to enhance dextromethorphan plasma levels.
Owner:AXSOME THERAPEUTICS INC

Method for detecting oxcarbazepine and related substances in oxcarbazepine oral solution and quality control method

The present application provides a detection method and quality control method for related substances in dextromethorphan oral solution, which comprises the following steps: dissolving dextromethorphan oral solution in a solvent to obtain a test solution; and performing high performance liquid chromatography detection on the test solution; the mobile phase used in the high performance liquid chromatography detection comprises mobile phase A and mobile phase B, the mobile phase A comprises a phosphate solution, the mobile phase B comprises acetonitrile, and the concentration of the phosphate solution is 0.1 mM-10 mM. The detection method has good linear relationship between dextromethorphan and related substances, good accuracy and sensitivity, strong specificity, high stability, good separation degree and good reproducibility, and is suitable for wide application.
Owner:WUHAN WUYAO SCI & TECH CO LTD

Method for preparing N-(2-(cyclohex-1-ene-1-yl) ethyl)-2-p-methoxyphenylacetamide

The invention belongs to the field of medicines, and particularly provides a method for preparing an important intermediate compound N-(2-(cyclohex-1-ene-1-yl) ethyl)-2-p-methoxyphenylacetamide of dextromethorphan. According to the method, 2-(1-cyclohexenyl) ethylamine and p-methoxyphenylacetic acid are used as raw materials, N, N-carbonyldiimidazole is selected as a condensation reagent, reaction conditions are optimized, the reaction temperature is reduced, the reaction time is shortened, aftertreatment is simple, the product yield and purity are high, cost is low, and industrial production is facilitated.
Owner:NHWA PHARMA CORPORATION

Treatment of poor metabolizers of dextromethorphan with a combination of bupropion and dextromethorphan

Disclosed herein is a method of safely treating a nervous system condition with a combination of dextromethorphan and bupropion. This method is intended for patients having a neurological condition or a psychiatric condition, such as major depressive disorder, and a CYP2D6 poor metabolizer genotype or a CYP2D6 poor metabolizer phenotype.
Owner:ANTECIP BIOVENTURES II LLC

Refining method of dextroborneol crude product

The invention relates to the technical field of organic synthesis, in particular to a refining method of a crude product of dextroborneol, which comprises the following steps: sequentially carrying out a rearrangement reaction, an esterification reaction, a salt forming reaction, an alkaline hydrolysis reaction and post-treatment refining on the crude product of dextroborneol in the presence of a solvent and a catalyst on the basis of a reaction product to obtain a refined product of dextroborneol, in the refined dextroborneol product, the content of dextroborneol is greater than or equal to 98.0%, the content of L-borneol is less than or equal to 1.0%, the content of isoborneol is less than or equal to 0.15%, the content of natural camphor is less than or equal to 0.15%, and the content of other impurities is less than or equal to 0.10%. The method has the advantages that the isoborneol structure can be selectively destroyed under mild conditions, impurities are effectively removed through the esterification-salification-alkaline hydrolysis three-step reaction, and the purity and yield of dextroborneol are remarkably improved.
Owner:TIANJIN PHARMA GROUP XINZHENG

Use of dextromethorphan in combination with CYP2d6 and CYP3a4 enzyme inhibitors for the treatment of pain

PCT designated stage expiredWO2025106609A1Nervous disorderAntipyreticEnzyme inhibitorDextromethorphan
Methods and compositions for treating pain are provided. Methods for treating pain include administering an effective amount of dextromethorphan or a pharmaceutically acceptable salt thereof in combination with a CYP2D6 enzyme inhibitor and a CYP3A4 enzyme inhibitor to a subject in need thereof. Compositions for treating pain that include dextromethorphan or a pharmaceutically acceptable salt thereof in combination with a CYP2D6 enzyme inhibitor and a CYP3A4 enzyme inhibitor are administered to a subject in need thereof.
Owner:BIOBINA LLC

Pharmaceutical composition containing dextromethorphan and application thereof

The present invention provides a pharmaceutical composition comprising dextromethorphan, the composition comprising dextromethorphan or a pharmaceutically acceptable salt thereof, and fluoxetine or a pharmaceutically acceptable salt thereof. According to the pharmaceutical composition provided by the invention, the dextromethorphan or the pharmaceutically acceptable salt of the dextromethorphan and the fluoxetine or the pharmaceutically acceptable salt of the fluoxetine are combined according to a specific proportion, so that the pharmaceutical composition not only has an excellent synergistic effect, but also reduces the dosage of the dextromethorphan and the fluoxetine which are independently used. The invention also provides application of the pharmaceutical composition in preparation of drugs for preventing and / or treating cough and neuropsychiatric disorders, especially depression.
Owner:SUZHOU NHWA PHARM RES CO LTD +1